Transparency

OUR COMMITMENT TO OPENNESS

The European Charcot-Marie-Tooth Federation (ECMTF) is committed to accountable governance, independent patient advocacy and transparent reporting of its funding. Explore how we consult our members, safeguard our independence and disclose our financial resources.

01 / GOVERNANCE

Accountability and consultation

ECMTF is a federation of patient organisations. Its constitution establishes how member organisations are represented and involved in decision-making.

01

Member representation

Member organisations appoint delegates to represent them within the Federation. Full Members have voting rights at General Meetings; Associate Members may participate without voting rights.

02

Consultation and decisions

The General Assembly meets at least annually. Members receive advance notice, proposed resolutions, and other relevant documents. Its responsibilities include approving annual accounts and electing the Board.

03

Oversight and reporting

The Board of Directors administers ECMTF and reports through established governance procedures. Meeting minutes and decisions are documented and communicated to members in accordance with the statutes.

Read the ECMTF Statutes (French, PDF)

02 / ETHICS & INDEPENDENCE

Our Code of Practice

ECMTF’s Code of Practice sets out the principles governing its relationships with the healthcare and pharmaceutical industries. It addresses independent decision-making, transparent acknowledgement of funding, protection from product promotion and safeguards for sponsored activities.

Financial support must not give any funder control over ECMTF’s priorities, public positions, event programmes or choice of speakers.

Coming soon..

Based on the principles of the EURORDIS Code of Practice between Patient Organisations and the Healthcare Industry.

03 / FINANCIAL TRANSPARENCY

How we are funded

2025 financial year · Based on the ECMTF 2025 Accounts. Percentages are calculated against income generated during 2025, excluding the balance carried forward from 2024.

Total 2025 income€53,914.18Excluding prior-year balance
Industry funding50.08%€27,000.00
Non-industry funding49.92%€26,914.18
Public funding37.62%€20,284.63 · EU4Health

FUNDING COMPOSITION

Industry vs non-industry

FY 2025
Industry funding50.08%
Non-industry funding49.92%

Funding from three healthcare-industry companies, alongside European public funding, membership fees, bank interest and private donations from private individuals.

PUBLIC FUNDING SHARE

European Union support

EU4Health grant supporting the 2nd European CMT Specialists Conference.

FUNDING CONCENTRATION

Largest company contribution

Applied Therapeutics: €20,000.00 of total annual income.

All reported income sources · 2025

Exact figures from the annual accounts; percentages shown to two decimals.

SourceClassification2025 incomeShare of total
European Union · EU4Health (2nd European CMT Specialists Conference)Public€20,284.6337.62%
Applied TherapeuticsIndustry€20,000.0037.10%
Ulysses Neuroscience LtdIndustry€5,000.009.27%
Full Member organisations (aggregate)Non-industry€3,012.945.59%
Interest income (Belfius Bank accounts)Non-industry€2,598.234.82%
NMD PharmaIndustry€2,000.003.71%
Associate Member organisations (aggregate)Non-industry€582.771.08%
Private individual donations (aggregate)Non-industry€435.610.81%
Total annual income€53,914.18100.00%

Membership fees and private donations are presented as aggregate amounts in the 2025 Accounts. ECMTF has confirmed that the €435.61 donations originated from private individual donors.

Healthcare-industry supporters · 2025

Companies whose 2025 contributions are recorded as conference grants in the ECMTF accounts.

Applied Therapeutics logo

Applied Therapeutics

€20,00037.10% of income
Ulysses Neuroscience logo

Ulysses Neuroscience Ltd

€5,0009.27% of income
NMD Pharma logo

NMD Pharma

€2,0003.71% of income

Industry contributions were primarily allocated to the 2025 specialist conference as unconditional support. Sponsor acknowledgement does not constitute endorsement of any company, medicine, product or service. The percentages above use total annual income, not the industry-only funding subtotal.

European Union logo

Public funding · European Union

ECMTF received €20,284.63 through EU4Health for the 2nd European CMT Specialists Conference (2025), equivalent to 37.62% of annual income. The event was co-funded under grant agreement 101232916.

View the conference and funding acknowledgement
04 / DOCUMENT LIBRARY

Annual accounts & reports

Download ECMTF’s last 5 year annual financial statements.

2025

2025 Annual Accounts

Latest approved financial statement · PDF

Download PDF
2024

2024 Annual Accounts

Latest approved financial statement · PDF

Download PDF
2023

2023 Annual Accounts

Latest approved financial statement · PDF

Download PDF
2022

2022 Annual Accounts

Latest approved financial statement · PDF

Download PDF
2021

2021 Annual Accounts

Latest approved financial statement · PDF

Download PDF

Funding disclosures refer to funds received by ECMTF during the reporting year. Other event supporters may be acknowledged separately where their contributions did not constitute ECMTF income.